135 related articles for article (PubMed ID: 29200145)
1. Treatment Outcome of Children With Multisystem Langerhans Cell Histiocytosis: The Experience of a Single Children's Hospital in Shanghai, China.
Gao YJ; Su M; Tang JY; Pan C; Chen J
J Pediatr Hematol Oncol; 2018 Jan; 40(1):e9-e12. PubMed ID: 29200145
[TBL] [Abstract][Full Text] [Related]
2. Lack of bone lesions at diagnosis is associated with inferior outcome in multisystem langerhans cell histiocytosis of childhood.
Aricò M; Astigarraga I; Braier J; Donadieu J; Gadner H; Glogova E; Grois N; Henter JI; Janka G; McClain KL; Ladisch S; Pötschger U; Rosso D; Thiem E; Weitzman S; Windebank K; Minkov M;
Br J Haematol; 2015 Apr; 169(2):241-8. PubMed ID: 25522229
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Langerhans cell histiocytosis with a modified risk-adapted protocol-experience from a tertiary cancer institute in India.
Narula G; Pradhan ND; Arora B; Banavali SD
Pediatr Blood Cancer; 2018 Aug; 65(8):e27028. PubMed ID: 29512864
[TBL] [Abstract][Full Text] [Related]
4. Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study.
Morimoto A; Shioda Y; Imamura T; Kudo K; Kawaguchi H; Sakashita K; Yasui M; Koga Y; Kobayashi R; Ishii E; Fujimoto J; Horibe K; Bessho F; Tsunematsu Y; Imashuku S
Int J Hematol; 2016 Jul; 104(1):99-109. PubMed ID: 27040279
[TBL] [Abstract][Full Text] [Related]
5. [Clinical study of 131 children with multi-system Langerhans cell histiocytosis].
Wu FF; Gao YJ; Pan C; Chen J; Tang JY
Zhonghua Er Ke Za Zhi; 2016 May; 54(5):349-53. PubMed ID: 27143076
[TBL] [Abstract][Full Text] [Related]
6. Egyptian experience in Langerhans cells histiocytosis: frequent multisystem affection and reactivation rates.
Tantawy AAG; Ragab IA; Elsherif NHK; Makkeyah SM; AbdelRaheem HG; Elsantiel HIE
Pediatr Hematol Oncol; 2020 Nov; 37(8):696-706. PubMed ID: 32706277
[No Abstract] [Full Text] [Related]
7. Multisystem Langerhans cell histiocytosis in children: current treatment and future directions.
Minkov M
Paediatr Drugs; 2011 Apr; 13(2):75-86. PubMed ID: 21351807
[TBL] [Abstract][Full Text] [Related]
8. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification.
Gadner H; Grois N; Pötschger U; Minkov M; Aricò M; Braier J; Broadbent V; Donadieu J; Henter JI; McCarter R; Ladisch S;
Blood; 2008 Mar; 111(5):2556-62. PubMed ID: 18089850
[TBL] [Abstract][Full Text] [Related]
9. [Clinical manifestations of Langerhans cell histiocytosis with multisystem involvement in 53 children].
Tang JJ; Xu XJ; Wang YC; Bai ST; Wang L; Ni XL; Liu YF
Zhonghua Er Ke Za Zhi; 2021 Jan; 59(1):37-41. PubMed ID: 33397002
[No Abstract] [Full Text] [Related]
10. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group.
Minkov M; Grois N; Heitger A; Pötschger U; Westermeier T; Gadner H
Klin Padiatr; 2000; 212(4):139-44. PubMed ID: 10994540
[TBL] [Abstract][Full Text] [Related]
11. 2'-Chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). results of the LCH-S-98 protocol of the Histiocyte Society.
Weitzman S; Braier J; Donadieu J; Egeler RM; Grois N; Ladisch S; Pötschger U; Webb D; Whitlock J; Arceci RJ
Pediatr Blood Cancer; 2009 Dec; 53(7):1271-6. PubMed ID: 19731321
[TBL] [Abstract][Full Text] [Related]
12. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis.
Gadner H; Minkov M; Grois N; Pötschger U; Thiem E; Aricò M; Astigarraga I; Braier J; Donadieu J; Henter JI; Janka-Schaub G; McClain KL; Weitzman S; Windebank K; Ladisch S;
Blood; 2013 Jun; 121(25):5006-14. PubMed ID: 23589673
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics and treatment outcome of Langerhans cell histiocytosis: 22 years' experience of 154 patients at a single center.
Lee JW; Shin HY; Kang HJ; Kim H; Park JD; Park KD; Kim HS; Park SH; Wang KC; Ahn HS
Pediatr Hematol Oncol; 2014 Apr; 31(3):293-302. PubMed ID: 24397251
[TBL] [Abstract][Full Text] [Related]
14. Langerhans cell histiocytosis: therapeutic strategy and outcome in a 30-year nationwide cohort of 1478 patients under 18 years of age.
Rigaud C; Barkaoui MA; Thomas C; Bertrand Y; Lambilliotte A; Miron J; Aladjidi N; Plat G; Jeziorski E; Galambrun C; Mansuy L; Lutz P; Deville A; Armari-Alla C; Reguerre Y; Fraitag S; Coulomb A; Gandemer V; Leboulanger N; Moshous D; Hoang-Xuan K; Tazi A; Heritier S; Emile JF; Donadieu J
Br J Haematol; 2016 Sep; 174(6):887-98. PubMed ID: 27273725
[TBL] [Abstract][Full Text] [Related]
15. Outcome of children with Langerhans cell histiocytosis and single-system involvement: A retrospective study at a single center in Shanghai, China.
Su M; Gao YJ; Pan C; Chen J; Tang JY
Pediatr Hematol Oncol; 2018; 35(7-8):385-392. PubMed ID: 30693828
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of children younger than 24 months with langerhans cell histiocytosis and bone involvement: a report from a single institution.
Kamath S; Arkader A; Jubran RF
J Pediatr Orthop; 2014 Dec; 34(8):825-30. PubMed ID: 25387157
[TBL] [Abstract][Full Text] [Related]
17. [Clinical characteristics and survival of children with langerhans cell hystiocytosis].
Krstovski N; Janić D; Dokmanović L; Brdar R
Srp Arh Celok Lek; 2008; 136(9-10):514-8. PubMed ID: 19069343
[TBL] [Abstract][Full Text] [Related]
18. Clinical features and treatment outcomes of Langerhans cell histiocytosis: a nationwide survey from Korea histiocytosis working party.
Kim BE; Koh KN; Suh JK; Im HJ; Song JS; Lee JW; Kang HJ; Park KD; Shin HY; Choi HS; Lee SH; Yoo KH; Sung KW; Koo HH; Jung HL; Chung NG; Cho B; Kim HK; Lyu CJ; Baek HJ; Kook H; Park JE; Park HJ; Park BK; Yoo ES; Ryu KH; Lee KS; Kim HS; Lee JM; Park ES; Yoon HS; Lee KC; Lee MJ; Lim YT; Kim HM; Park SK; Park JA; Kim SK; Park M; Lim YJ; Lee YH; Seo JJ;
J Pediatr Hematol Oncol; 2014 Mar; 36(2):125-33. PubMed ID: 24276037
[TBL] [Abstract][Full Text] [Related]
19. Circulating cell-free BRAF
Héritier S; Hélias-Rodzewicz Z; Lapillonne H; Terrones N; Garrigou S; Normand C; Barkaoui MA; Miron J; Plat G; Aladjidi N; Pagnier A; Deville A; Gillibert-Yvert M; Moshous D; Lefèvre-Utile A; Lutun A; Paillard C; Thomas C; Jeziorski E; Nizard P; Taly V; Emile JF; Donadieu J
Br J Haematol; 2017 Aug; 178(3):457-467. PubMed ID: 28444728
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes and prognostic risk factors of Langerhans cell histiocytosis in children: Results from the BCH-LCH 2014 protocol study.
Cui L; Wang CJ; Lian HY; Zhang L; Ma HH; Wang D; Chen FF; Zhang Q; Yang Y; Wei A; Huang XT; Zhu T; Wang TY; Li ZG; Zhang R
Am J Hematol; 2023 Apr; 98(4):598-607. PubMed ID: 36594188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
